Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanifibranor with or without empagliflozin in NASH and type 2 diabetes
NL-OMON53417Phase 2Recruiting
- Sponsor
- Inventiva
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM) comparing Lanifibranor, Placebo and Lanifibranor + empagliflozin (3 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2023; status: recruiting.
02
Drugs
lanifibranorempagliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON53417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53417.